Is there a magic formula for achieving HTA approvals in Europe?
Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on the increase, and market access professionals are scratching their heads wondering what can realistically be done to ease the process.
We spoke to experts at seven top tier pharmaceutical companies to find out their latest thinking on European HTAs, the difficulties faced, and how they are being overcome. We used their detailed responses to collate a fresh perspective on the current trends and to identify the key success factors involved in securing a positive HTA recommendation in Europe. Various issues were identified:
What to expect from this report
The proliferation of HTAs across Europe makes market entry complex to address. [DN: This report doesn't include the US and I don't agree that Europe is less complex so have amended accordingly] This report delivers the overview and specific insights needed for European teams to see their markets in context, and to set the foundation for a more nuanced and more productive HTA strategy.
This is 100% new qualitative research based on expert interviews conducted in April and May 2018. All the experts selected are currently actively involved in securing HTA approval.
Example insight included in HTA in Europe: Key Success Factors for Positive HTA Recommendations
Overcoming HTA agencies' concerns about evidence might need particular methodologies such as indirect comparisons and network meta-analysis, particularly in the absence of head-to-head trials, but this is not acceptable to all. In Germany, indirect comparisons and network meta-analysis are not acceptable, whereas they are accepted in the UK and in the Nordic countries.
Example quote included in HTA in Europe: Key Success Factors for Positive HTA Recommendations
"You need to develop your own cost effectiveness model and identify within each product and each indication what are the drivers of cost effectiveness, and those may change. And that's why I cannot give you a straight answer on what is the key driver because it could be price, but it could be something else."
HEOR Expert Switzerland
The expert panel for HTA in Europe: Key Success Factors for Positive HTA Recommendations
Why buy now?
The pharma industry has not traditionally provided many opportunities for peers to comfortably share their professional experiences and come up with new ideas to combat common problems. Which is why reports like this make such a difference. We've explored the issues, asked the important questions, and got a sense of what the latest thinking is—so you don't have to.
Why FirstWord reports are different
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved